Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Mol Carcinog. 2014 Dec 9;55(1):3–14. doi: 10.1002/mc.22253

Figure 6.

Figure 6

The effect of silibinin and DHS on in vivo proliferation, NF-κB p50, and c-Fos activation. (A) ASZ allograft tissues from control and treatment groups were subjected to IHC analysis. Representative photographs are shown for PCNA, cyclin D1, NF-κB p50, and c-Fos. (B) Quantitative data for each biomarker showing the mean ± SEM of 7–10 individual tumor samples from each group. *P ≤ 0.05, **P ≤ 0.001, significant with respect to vehicle control.